Let's Get Started

Biotech

Rockwell Medical RMTI Breakout Alert

Rockwell Medical RMTI Breakout Alert

Jan 13, 2022

Rockwell Medical RMTI is up 59% after due to a massive amount of volume being injected into this little well known stock that has been crashing for the last twelve months. I have written a full report on RMTI that you can read below.

However, before you read this insightful information, sign up below, let’s stay in contact.

LVGI

Limitless Venture Group announced today, “ Announced that its partner in South Korea, Jeil Pharmaceutical” However, before we get started, let’s review some basic information on this company.

Rockwell RMTI Company Summary

Company Name:  Rockwell Medical , Inc

Ticker: RMTI

Exchange: NASDAQ

Website: www.RockwellMed.com.

Rockwell Company Summary

Rockwell Medical RMTI is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform. The iron technology is Ferric Pyrophosphate Citrate. It has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives.

The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis. These are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis. These patients are receiving intravenous medications in the home infusion setting.

In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States.

RMTI News

Jan. 13, 2022

Announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received regulatory approval by the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea for Triferic Injection.

Also, Triferic Injection (ferric pyrophosphate citrate sodium sulfate co-precipitate hydrate injection) marketed in the United States as Triferic AVNU (ferric pyrophosphate citrate injection) for iron supplementation therapy. Hence, it creates hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. HERE

Rockwell Medical 1 Month Chart

RMTI

RMTI 1 Day Chart

RMTI

Rockwell Technical Analysis

The news was incredible that RMTI Announced that its partner in South Korea, Jeil Pharmaceutical Co , has received regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic Injection.

Also, The real question is, what is it going to do now? Well, it has pulled back as expected but it will now consolidate then make a move up or down depending on the indicators within the consolidation. It is too early to determine which way it will move, but it is showing an early tendency to go bullish.

Hence, The stock responded with a massive amount of volume and a PPS increase of 59%. RMTI skyrocketed from $.40 to $.65 with 50 million+ shares traded.

I would expect RMTI to go up with the news today. It was huge and the stock responded with a massive amount of volume and a PPS increase of 251%. LVGI skyrocketed from $.011 to $.0388 with 50 million+ shares traded.

I am thinking RMTI will continue to go down as it has for over a year but there is opportunities with quick scalps. Stay tuned traders

Moreover, Remember, to never try and catch a falling safe, or a knife for that matter. Simply let it fall to the ground, walk over, and pick up the money. If you enjoyed this article, sign up below, I promise I will never spam you. Also, I’m pretty darn good at picking winners. Let’s make some trades together!

LVGI

read more
Reviva Pharma RVPH down big.

Reviva Pharma RVPH down big.

Jan 10, 2022

Reviva Pharma RVPH down big on massive volume, to find out why take a look at this technical analysis by our Alexander Goldman down below

Reviva Pharmaceuticals RVPH Company Summary

Company Name:  Reviva Pharmaceuticals Holdings, Inc.

Ticker: RVPH

Exchange: NASDAQ

Website: https://ir.revivapharma.com/

Reviva Pharmaceutical Company Summary

Reviva Pharma RVPH is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families.

Also, Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208.

Therefore, Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and RP1208 in the United States (U.S.), Europe, and several other countries.

Why did RVPH go down?

Jan. 10th 2021

Reviva Pharma RVPH announced today the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with Phase 3 clinical investigation of its lead candidate, brilaroxazine, a novel serotonin and dopamine receptor modulator for the treatment of schizophrenia.

RVPH 3 Month Chart

PSTI

RVPH 1 Day Chart

PSTI

RVPH Technical Analysis

Reviva Pharmaceutical is looking bad, real bad. Don’t put it on your watchlist. It’s bearish all the way around.

read more
Pluristem Therapeutics PSTI Collaboration

Pluristem Therapeutics PSTI Collaboration

Jan 10, 2022

Pluristem Therapeutics PSTI signs a massive collaboration deal. Also, the stock looks great. Take a look below.

Pluristem Therapeutics PSTI Company Summary

Company Name:  Pluristem Therapeutics Inc.

Ticker: PSTI

Exchange: NASDAQ

Website: https://www.pluristem.com/  

Pluristem Therapeutics Company Summary

Pluristem is pushing the boundaries of science and engineering to create cell-based products for commercial use. The Company’s cell therapies advance the field of regenerative medicine, with potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation.

Moreover, pluristem Therapeutics’ sources its therapeutic cells from the placenta, an ethically accepted and potent source.

The Company’s manufacturing platform is a patented and validated state-of-the-art 3D cell expansion system. Pluristem’s method is uniquely accurate, cost-effective, and consistent from batch to batch.

Why did PSTI go up?

Jan. 10th 2021

Announced the launch of an innovative collaboration to develop, manufacture and commercialize cultured cell-based products for the food industry.

Therefore, the collaboration started with the incorporation of a new company (“NewCo”), that will receive exclusive, global, royalty bearing licensing rights to use Pluristem’s proprietary technology, intellectual property and knowhow, to be used in the field of cultured meat.

PSTI 3 Month Chart

Pluristem Therapeutics PSTI

PSTI 1 Day Chart

Pluristem Therapeutics PSTI

PSTI Technical Analysis

The $1.87 PPS for Pluristem Therapeutics PSTI is important before I would consider the trade. However, this stock is looking great! It gapped up big and pulled back for a minute and consolidated all day with a bullish lean.

Pluristem Therapeutics PSTI is possibly a winner, but I wouldn’t expect big things, probably sub 50% gains in the next few weeks.

read more
Breakout for Mainz Biomed MYNZ?

Breakout for Mainz Biomed MYNZ?

Jan 4, 2022

Mainz Biomed MYNZ develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. So, our traders have the ability to invest and feel good about helping the world while simultaneously investing!

The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.

The top 4 reasons Mainz Biomed B.V. (NASDAQ: MYNZ) is primed for a Massive breakout!

#1 MYNZ is Undervalued  

#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!

#3 Mainz Biomed Is Generating Revenue

#4 Philanthropic Investing feels good

Before we go over the top 4 reasons, let’s get acquainted with Mainz Biomed.

Company Name: Mainz BioMed

Ticker: MYNZ

Exchange: NASDAQ

Website: https://mainzbiomed.com/investors/

Mainz Biomed MYNZ Company Summary:

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.

ColoAlert is currently marketed across Europe with an FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval.

Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

[thrive_leads id=’9846′]

Why did it go up over 30% in just 21 trading days?

DECEMBER 7th, 2021

At-home Colorectal Cancer Diagnostic Test Now Available Online in Germany

Mainz Biomed announced the launch of ColoAlert.de, an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test. German residents unable to obtain timely CRC screening via in-person physician visits, will be able to order ColoAlert directly to their home and receive highly accurate results within a maximum of nine working days. For more Info HERE

DECEMBER 14th, 2021

Mainz to co-brand ColoAlert with GANZIMMUN Diagnostics, one of the largest stool analysis labs in Germany with their 5,500 labs.Mainz Biomed announced a partnership with leading diagnostics laboratory GANZIMMUN Diagnostics AG (GD), one of Europe’s leading laboratories for preventive and complementary medicine, for the commercialization in Germany of ColoAlert, Mainz’s unique, highly efficacious, and easy-to-use detection test for colorectal cancer. For More Info HERE

Now that we have a good understanding of why MYNZ is up 30%, let’s go over the top 4 reasons Mainz Biomed could be ready for a massive breakout!

#1 MYNZ is Undervalued  

#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!

#3 Mainz Biomed B.V.  Is Generating Revenue

#4 Philanthropic Investing feels good

#1 MYNZ is in a Multi-Billion Dollar Industry

Mainz Biomed has a Market Cap of $121 Million but when you look at other companies that are in the space, you can see the value in this diamond in the rough. I am very excited to see this kind of potential priced at such a low PPS and with a very small float at 12 Million shares outstanding.

Furthermore, Mainz plans on starting the FDA process shortly after their public listing.  Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to a market potential of over 52 million tests per year. 1  Can you imagine what will happen to the price per share of MYNZ when they get approved? Let’s look at one of their competitors to see what actually did happen!

Take a look at Mainz Biomed’s competitor Exact Sciences Corporation NASDAQ

Today, the top non-invasive colorectal screening test technology is manufactured by Exact Sciences (NASDAQ:EXAS), which is a perfect success story that Mainz BioMed is currently seeking to recreate. EXAS is valued at $17 BILLION and trades at $78 PPS! Could you imagine if MYNZ is trading at those PPS in the near future? That would be almost 700% gains, like turning $10,000 into $80,000. 

I do apologize, I tend to get excited about companies that are showing massive potential in a philanthropic industry. Invest and possibly make money while saving lives, it’s the cornerstone of the capitalism that Adam Smith promoted. Not this crony Capitalism!

Did you see the EXAS’ share price back in 08’ it fell to less than one dollar. Essentially, investors were basically saying Exact was worthless.But in June 2009, an announcement of a mutual collaboration and licensing agreement between Exact Sciences and the Mayo Clinic turned the company’s fortunes around.

However, it was in 2014 when the FDA approved Cologuard for use as a non-invasive colorectal cancer screening test, and the test’s inclusion in multiple national guidelines that truly made the stock take off.

Hmm… Isn’t Mainz seeking FDA approval! See the correlation? I do and you should too.

For investors of EXAS who got in as recently as mid-2016 have already seen their investment grow nearly 20x in just over 5 years. Today it’s worth nearly $17 billion USD.

20x Returns, that $10,000 would be $200,000

Here is the kicker, Mainz Biomed’s ColoAlert is designed to be easier to administer than Exact Sciences ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy. This is truly cutting edge medical testing at a fraction of the PPS of Exact Science.

MYNZ other competitor is Genescopy a privately help company making some moves

The reason I mention Geneoscopy is because this story is relevant, take a look at the investment level, $100M++!

Geneoscopy Inc. is a life sciences company focused on the development of diagnostic tests for gastrointestinal health, announced November 17th the closing of a Series B financing, raising a total of $105 million through a combination of debt and equity.

The round is led by previous investors Lightchain Capital and NT Investments. Other investors in the round include Morningside Ventures, Labcorp, Cultivation Capital, BioGenerator Ventures, and Innovatus Capital Partners. HERE

That is an example of just how large this industry is and how much money is available to fund it. It’s cancer and it has affected almost everyone in one way or the other.

#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!

MYNZ 1 Month Chart Technical Analysis

As you can see the trend is very Bullish and has consolidated since the December 21st-December 28th run. The 30% run last month that started December 6th was very controlled and on moderate volume.

Next, let’s look at the 5 day chart to see what is happening lately.

MYNZ 5 Day Chart Technical Analysis

I’ve been waiting on this reversal and I was betting it would happen today and literally in the final hour of trading it happened. I love this chart! As you see from the month chart above a bullish move and then consolidation with a slight bearish lean. Consequently, I’ve been waiting for a confirmation of a reversal. As MYNZ reached $10.43 it confirmed the reversal and this may just take off like a rocket ship.

If you think the stock chart is good, wait until you see why. MYNZ is generating revenue and the street is watching.

#3 Mainz Biomed B.V.  Is Generating Revenue

ColoAlert has received CE accreditation and is approved for sale in Europe.1  European sales will provide near-term revenue potential, while they prepare for entry into the US market. Just last month, Mainz Biomed announced the launch of ColoAlert.de, an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test.

This is significant, DTC (direct to consumer) test to see if you have cancer which will allow you to catch it early and have a 90% survival rate. However, only about 4 out of 10 colorectal cancers are found at this early stage. When cancer has spread outside the colon or rectum, survival rates are lower.

ColoAlert is designed for profitability, rapid commercial uptake, and broad consumer acceptance. The fact that Mainz Biomed is generating revenue in Europe and will be entering the US market with FDA approval is a massive sign for things to come. Make sure you keep MYNZ on your watchlist because the potential is substantial.

#4 Philanthropic Investing – possibly turn an amazing profit while helping people

It is rare for investors to be able to possibly have a home run  return on an investment while helping to alleviate senseless deaths with the 2nd most deadly form of cancer.Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%. However, only about 4 out of 10 colorectal cancers are found at this early stage. When cancer has spread outside the colon or rectum, survival rates are lower.

90% survival rate if detected early, guess what, ColoAlert detects early stage colon cancer. There is a solution and it is ready to come to market in the USA with FDA approval.

Why is Mainz Biomed your cake and icing for investors?

  1. ColoAlert Holds Potential as a Blockbuster Early Detection Test for Colorectal Cancer. Far less senseless deaths in regards to colon cancer!
  2. Mainz BioMed protects its intellectual property through trade secrets to control all critical reagents, processes and formulations. Protecting intellectual property is important for market capitalization! 
  3. Mainz Biomed MYNZ is developing proprietary genetic testing methods for pancreatic cancer. Once the distribution channel is developed, offering multiple products creates more than one revenue stream!
  4. Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity. Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy. 1

Let’s recap why Mainz Biomed MYNZ could be, THE massive breakout of 2022!

#1 MYNZ is Undervalued  

#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!

#3 Mainz Biomed B.V.  Is Generating Revenue

#4 Philanthropic Investing feels good

It is a rare opportunity in this world to have this kind of investment opportunity while also funding the act of saving lives. This is an easy fix, detect the 2nd most dangerous form of cancer early and you have a 90% survival rate. ColoAlert is the answer, we just need to stop what we are doing and place it on your watchlist, today!

 Happy Trading and remember, never try to catch a falling knife!

1 https://mainzbiomed.com/investors/

Disclaimer

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

We publish the Information on our website, smallcapexclusive.com/ and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, MYNZ. Small Cap Exclusive has been hired by Awareness Consulting for a period beginning on January 4, 2021 to publicly disseminate information about (MYNZ) via website and email. We have been compensated $13,500 USD. We will update any changes to our compensation.

Read full disclaimer here.

read more
Meso Numismatics (MSSV) skyrocketing

Meso Numismatics (MSSV) skyrocketing

Dec 29, 2021

Meso Numismatics (MSSV) up over 200% in a week

Company Name: Meso Numismatics (MSSV)

Ticker: MSSV

Exchange: OTC Website: www.stemcellsgroup.com

Company Summary:

Meso Numismatics, Inc. acquired Global Stem Cells Group (Global) is a premier Regenerative Medicine company that specializes in cutting edge stem cell research, current clinical applications, and physician training.

Global licenses its intellectual property and name to medical professionals around the world providing them with necessary equipment and cellular therapy products needed to perform safe and effective Regenerative Medicine related treatments.

Global has one of the largest physician membership networks in the world with 29 offices in more than 25 countries.

Why did it go up over 200%?

There is no news out or press releases. It appears to be an awareness campaign. I do find Meso Numismatics acquisition of Global Stem Cells Group (Global) four months ago as a good omen. Global is a premier Regenerative Medicine company that specializes in cutting edge stem cell research, current clinical applications, and physician training.

Meso Numismatics (MSSV) 5 Day Chart

Meso Numismatics (MSSV) technical analysis shows there is resistance at $.33 & $.345, be sure to break through those resistance points before considering a purchase.
MSSV is trending bullish in the 5 day chart and month chart but is showing bearish tendencies in the one day chart. There is thin volume on this stock so be aware of that as you proceed.

read more
Dais Corp DLYT up over 2,000%

Dais Corp DLYT up over 2,000%

Dec 21, 2021

Company Name: Dais Corporation 

Ticker: (DLYT)

Exchange: OTC

Website: https://daisanalytic.com/

Company Summary:

Dais Corporation is a nanotechnology business producing a versatile platform of nanotechnology membrane materials (called Aqualyte™) addressing evolutionary and disruptive air, energy, and water applications. These proven products are characterized by offering Climate Change emission and energy reductions, longer lifetimes, and competitive pricing in the HVAC, Water, and Energy industries. Current commercial revenues come from selling:

  • Advanced Aqualyte™ nanomaterials to a wide range of OEMs wishing to create new or highly differentiated products which embrace the moisture management features of the product.
  • ConsERV™, a commercially available HVAC engineered energy recovery ventilation system that uses energy in exhaust air to precondition the temperature and moisture content of incoming fresh air. ConsERV™ typically saves energy, reduces CO2 emissions, and allows the overall HVAC system to be safely downsized. ConsERV™ introduces fresh ventilation air, resulting in higher productivity and sharper decision-making skills of building occupants, lowers triggers for allergies and asthma, and offers strong protection against key pathogens, including COVID-19 and most aggressive forms of bacteria.

Why is Dais on a rocket ship?

Nov. 29, 2021 Dais Corporation announced the Company has removed $2.12M of convertible, variable debt from its balance sheet.

3 Month Chart

5 Day Chart

Technical Analysis:

It is Bullish overall but this stock finished bearish and is up over 2,000%++. Be VERY careful and I wouldn’t look at this till it beats $6.20 or it will fall or best case consolidate. 

read more
UPDATE: Alex believes Petros Pharma (PTPI) is ready to BOUNCE, PAY ATTENTION!

UPDATE: Alex believes Petros Pharma (PTPI) is ready to BOUNCE, PAY ATTENTION!

Dec 15, 2021

Company Name: Petros Pharmaceuticals, Inc. 

Ticker: (PTPI)

Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.

Why did it go up over 100%?

reported positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. This study is a key component in the Company’s plans to engage in discussions with the FDA to expand the product’s access through application for a possible OTC pathway. Early study indicators show positive label comprehension outcomes in the study, which has encouraged the Company to initiate the next step, a Self-Selection Study, as it continues to build the case for the FDA for OTC access to STENDRA.

“The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make 

The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?

I’m a big fan of this company and the recent news it released. Let’s take a look at the chart.

I wrote on Monday 12/13/21 a 5 Day Technical Analysis:

“It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish! Let’s take a close look at the 1 day.”

Yes, I was right it went BEARISH!

I wrote on Monday 12/13/21 a 1 Day Technical Analysis:

“It’s very simple, can it beat $4.38? Yes, then I would wait for a pull back and then swing trade it for a quick scalp. If it can’t, I would expect a pullback then consolidation and then a run! Overall, I love the stock because of the news. The first OTC ED med, say what!?!?”

Let’s look at where it is around lunch on Wednesday 12/15/21

WOW I called it, it didn’t break $4.38 and it did PULLBACK 38%! 

Called it AGAIN, Now it is consolidating!

Alex Goldman Prediction:

It is about to run! It is bullish and I like it! Put it on your watchlist and Let’s make some money!!!!

read more
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) announces 2b clinical trials!

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) announces 2b clinical trials!

Dec 14, 2021

Company Name: BELLUS Health Inc. 

Ticker: (BLU)

Exchange: NASDAQ

Website:  www.bellushealth.com

Company Summary:

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC and is planning a Phase 3 program that is expected to begin in 2022.

Why did it go up almost 100%?

Link HERE – LAVAL, Quebec, December 13, 2021–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that the 50 mg and 200 mg BID doses of BLU-5937 in its Phase 2b SOOTHE trial for the treatment of RCC achieved statistical significance on the primary endpoint with 34% placebo-adjusted reduction in 24-hour cough frequency observed (p ≤ 0.005) at day 28. BLU-5937 was generally well-tolerated, with low rates of taste-related adverse events reported (≤6.5%) at all doses.

Mr. Roberto Bellini, Chief Executive Officer of BELLUS Health commented, “We are extremely pleased with the compelling topline results from the Phase 2b SOOTHE trial which highlight BLU-5937’s best-in-class potential for the treatment of refractory chronic cough. RCC is a prevalent and growing condition that significantly impacts the quality of life of an estimated 9 million patients in the United States and 9 million patients in Europe.”

5 Day Technical Analysis:

There are a lot of traders at $9.05, so if this stock can beat $9.05 tomorrow, I like it. If not, and I’m thinking it won’t, stay away. Caveat, the news is really good, so I hold out hope, but I don’t like the huge 70% gap up. Happy trading and always play it safe with trailing stops!

read more
Biofrontera Inc. (Nasdaq: BFRI Patent allowed!

Biofrontera Inc. (Nasdaq: BFRI Patent allowed!

Dec 14, 2021

Company Name: Biofrontera Inc. 

Ticker: (BFRI)

Exchange: NASDAQ

Website: www.biofrontera-us.com

Company Summary: 

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.

Why did it go up over 100%?

WOBURN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biofrontera Pharma GmbH’s U.S. patent number 17/215,785 (‘785 patent), titled “Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device,” which protects a number of innovations relating to the RhodoLED XL lamp.

WOBURN, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the first subject has been enrolled in the Phase 2b study performed by Biofrontera Bioscience GmbH to evaluate the safety and efficacy of Ameluz® in combination with the red-light lamp BF-RhodoLED® for the treatment of moderate-to-severe acne with photodynamic therapy (Ameluz®-PDT).

5 Day Chart Technical Analysis

I like the stock! Great news and the 5 day is bullish and has solid news with a patent being accepted and a phase 2b clinical trial being announced. 

1 Day Chart Technical Analysis

Technical Analysis:

I like the stock only IF the bearish trend continues in the morning, stay AWAY until there is consolidation and a double confirmation of a bullish move. 

read more